<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343642</url>
  </required_header>
  <id_info>
    <org_study_id>R21AT001628-01A2</org_study_id>
    <secondary_id>R21AT001628-01A2</secondary_id>
    <nct_id>NCT00343642</nct_id>
  </id_info>
  <brief_title>Dietary Treatment of Crohn's Disease</brief_title>
  <official_title>Dietary Treatment of Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective is to determine whether a specific dietary intervention or a&#xD;
      fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it&#xD;
      is beneficial in the treatment of Crohn's Disease (CD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several epidemiological studies and therapeutic observations in the complementary and&#xD;
      alternative medicine (CAM) literature suggest that diet is key to development of CD and its&#xD;
      treatment. The investigators took advantage of these CAM recommendations and designed dietary&#xD;
      interventions. Our preliminary open label studies in IBD patients showed that our&#xD;
      interventions are acceptable and well-tolerated and result in improvement, reducing symptoms&#xD;
      and/or the degree of inflammation. The investigators are now seeking to validate this finding&#xD;
      and determine the mechanisms underlying the effects of dietary manipulation-such as potential&#xD;
      effects on colonic bacterial microflora. In another pilot study using 16s rDNA bacterial&#xD;
      fingerprinting, the investigators demonstrated that the intestinal microflora of patients&#xD;
      with CD differ significantly from healthy individuals. Whether the investigators can&#xD;
      normalize/change the microflora of CD patients with dietary therapies, however, remains to be&#xD;
      determined. Accordingly, the investigators designed a double blind placebo controlled study&#xD;
      to test the hypotheses that: (1) dietary manipulation with either diet or a FOS supplement is&#xD;
      an effective CAM therapy that prevents CD relapse (leads to maintenance of remission) and (2)&#xD;
      such dietary manipulation can normalize the microflora of CD patients and decrease mucosal&#xD;
      oxidative damage.&#xD;
&#xD;
      90 participants are expected to undergo the trial and have a 2:1 chance of receiving active&#xD;
      therapy. The trial is seeking to enroll participants with inactive CD who have been medically&#xD;
      induced into remission within 9 months of enrollment. Participants must be on their Crohn's&#xD;
      medications at a stable dose for 3 months, which does not include steroids (e.g. Prednisone,&#xD;
      Entocort) or antibiotics at the time of enrollment. Participants will be followed till&#xD;
      relapse occurs or up to 52 weeks. Participants are asked to fill out a variety of&#xD;
      questionnaires, keep a food and adverse event diary, and have a research, limited, unprepped&#xD;
      flexible sigmoidoscopy for colonic tissue collection at the beginning and end of the study&#xD;
      period.&#xD;
&#xD;
      Significance. This study could provide information to suggest diet or dietary supplement as a&#xD;
      safe therapy for IBD and lay the groundwork for more definitive, randomized, controlled&#xD;
      trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Flare Up of Crohn's Disease Through Month 12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The efficacy of the dietary treatment was assessed by looking at the number of participants who flared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life in Patients Taking Dietary Treatments</measure>
    <time_frame>At exit visit of study</time_frame>
    <description>Inflammatory Bowel Disease Questionnaire (IBDQ) overall scores at the exit visit of the study.It consists of 32 questons divided into four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items) and social function (5 items). Every question has graded responses from 1 (worst situation) to 7 (best situation), and thus the total score is ranging from 32 to 224 with higher scores representing better quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Dietary Treatments</measure>
    <time_frame>90 days</time_frame>
    <description>Data not collected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Ileocolonic Flora</measure>
    <time_frame>90 days</time_frame>
    <description>Data not collected</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Active Fructo-oligosaccharide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received an active fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.&#xD;
The fructo-oligosaccharide supplement was administered orally in a powder form two teaspoons daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Fructo-oligosaccharide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received a placebo fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received a placebo fructo-oligosaccharide supplement and a restrictive anti-inflammatory diet developed by the research team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active fructo-oligosaccharide</intervention_name>
    <description>2 teaspoons of active fructo-oligosaccharides daily and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans</description>
    <arm_group_label>Active Fructo-oligosaccharide</arm_group_label>
    <other_name>Active fructooligosaccharide (FOS) and Placebo Diet</other_name>
    <other_name>Time and Attention and Active Fructooligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo fructo-oligosaccharide</intervention_name>
    <description>2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily) and Time and attention administering usual dietary recommendations for a healthy diet based on 2005 Dietary Guidelines for Americans</description>
    <arm_group_label>Placebo Fructo-oligosaccharide</arm_group_label>
    <other_name>Placebo Diet and Placebo Supplement</other_name>
    <other_name>Tiem and Attention and Fructooligosaccharide Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>A restrictive anti-inflammatory diet developed by the research team and 2 teaspoons of placebo fructose powder ( to serve as the placebo equivalent of active treatment with fructo-oligosaccharides daily)</description>
    <arm_group_label>Dietary Therapy</arm_group_label>
    <other_name>Active Dietary Intervention and Placebo Supplement</other_name>
    <other_name>Dietary Treatment and Fructooligosaccharide Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented ileocolonic or colonic CD based on classical history and classical&#xD;
             endoscopic or surgical findings and histology compatible with CD;&#xD;
&#xD;
          2. Induction of remission with medical therapy within 9 months of the study;&#xD;
&#xD;
          3. Inactive CD for at least 2 weeks with CDAI score less than 150;&#xD;
&#xD;
          4. No change in IBD medication doses for 3 months;&#xD;
&#xD;
          5. No change in smoking habits a month prior to enrollment (because smoking may&#xD;
             exacerbate CD) and acceptance of not-changing smoking habits during the term of the&#xD;
             study).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with history of bowel obstruction and/or known strictures (as the high fiber&#xD;
             content may precipitate obstruction);&#xD;
&#xD;
          2. Patients with extensive colonic or ileocolonic resection;&#xD;
&#xD;
          3. Patients with ileostomies or colostomies with diverted fecal stream;&#xD;
&#xD;
          4. Patients with isolated perianal/anorectal disease;&#xD;
&#xD;
          5. Patients with surgically induced remission;&#xD;
&#xD;
          6. Concomitant infection (e.g., C. difficile colitis);&#xD;
&#xD;
          7. Use of antibiotics within 4 weeks, or steroids, herbal remedies or diet therapies&#xD;
             within 2 weeks of the onset of the trial or during the study;&#xD;
&#xD;
          8. Use of potential IBD exacerbators such as NSAIDs within 1 wk of the study;&#xD;
&#xD;
          9. Acute illness requiring immediate hospitalization for CD or other reasons;&#xD;
&#xD;
         10. Presence of symptomatic organic GI disease other than CD, hemorrhoids, hiatal hernia;&#xD;
             GERD;&#xD;
&#xD;
         11. Pre-existent organ failure or severe comorbidities as these may change Gl flora:&#xD;
&#xD;
               -  Liver disease (cirrhosis or persistently abnormal AST or ALT that are 2X&gt;&#xD;
                  normal);&#xD;
&#xD;
               -  Kidney disease (creatinine&gt;2.0 mg/dL);&#xD;
&#xD;
               -  Uncontrolled psychiatric illness;&#xD;
&#xD;
               -  Clinically important lung disease or heart failure;&#xD;
&#xD;
               -  HIV disease;&#xD;
&#xD;
               -  Alcoholism;&#xD;
&#xD;
               -  Transplant recipients;&#xD;
&#xD;
               -  Patients receiving other immunosuppressant medications for comorbidities (e.g.&#xD;
                  Enbrel for rheumatoid arthritis);&#xD;
&#xD;
         12. Presence of short bowel syndrome or severe malnutrition with ideal body weight less&#xD;
             than or equal to 90% or predicted;&#xD;
&#xD;
         13. Estimated survival &lt;1 year and Karnofsky performance status &lt;50%;&#xD;
&#xD;
         14. Desire to become pregnant during study or current pregnancy or nursing;&#xD;
&#xD;
         15. Desire to change smoking-status during the study;&#xD;
&#xD;
         16. Daily use of anticoagulation and antiplatelet medications;&#xD;
&#xD;
         17. Complicated IBD with anticipation of imminent surgical intervention during the term of&#xD;
             the study;&#xD;
&#xD;
         18. Inability to have a regular follow-up and comply with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ece A Mutlu, MD MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Keshavarzian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shahriar Sedghi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gastroenterology Associates of Central Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastroenterology Associates of Central Georgia</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 21, 2006</study_first_submitted>
  <study_first_submitted_qc>June 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <results_first_submitted>April 25, 2016</results_first_submitted>
  <results_first_submitted_qc>May 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2021</results_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>Fructooligosaccharide</keyword>
  <keyword>Inulin</keyword>
  <keyword>Diet</keyword>
  <keyword>Treatment</keyword>
  <keyword>Bacterial flora</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>54 subjects were randomized into a 12 month randomized, double blind, placebo controlled trial to test the efficacy of a specialized restrictive diet and a Fructo-oligosaccharide (FOS) supplement in maintenance of remission in patients with Crohn's disease (CD). Participants were recruited at Rush University, Chicago between Sept 2005-2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Time and Attention and Active Fructo-oligosaccharide</title>
          <description>Subjects received an active prebiotic fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans</description>
        </group>
        <group group_id="P2">
          <title>Time and Attention and Fructo-oligosaccharide Placebo</title>
          <description>Subjects received a placebo fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.</description>
        </group>
        <group group_id="P3">
          <title>Dietary Therapy and Fructo-oligosaccharide Placebo</title>
          <description>Subjects received a placebo fructo-oligosaccharide supplement and a restrictive anti-inflammatory diet developed by the research team.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Upto 3 Months Complete or Flare</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3-6 Months Complete or Flare</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Flare up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants were patients with Crohn's disease in remission.</population>
      <group_list>
        <group group_id="B1">
          <title>Time and Attention + Active Fructooligosaccharide Supplement.</title>
          <description>Time and attention + active fructooligosaccharide supplement.&#xD;
Time and attention + active fructooligosaccharide supplementation: 2 teaspoons of fructooligosaccharides daily</description>
        </group>
        <group group_id="B2">
          <title>Time and Attention + Fructooligosaccharide Placebo</title>
          <description>Time and attention + fructooligosaccharide placebo&#xD;
Time and attention + fructo-oligosaccharide placebo: 2 teaspoons of placebo powder daily</description>
        </group>
        <group group_id="B3">
          <title>Dietary Therapy + Fructooligosaccharide Placebo</title>
          <description>Dietary therapy + fructooligosaccharide placebo&#xD;
dietary therapy + fructo-oligosaccharide placebo: Medical nutrition therapy and 2 teaspoons of placebo powder</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.21" spread="12.43"/>
                    <measurement group_id="B2" value="48" spread="16.89"/>
                    <measurement group_id="B3" value="45.13" spread="14.17"/>
                    <measurement group_id="B4" value="45.46" spread="14.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <description>Participants were grouped as per their current smoking status.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Flare Up of Crohn's Disease Through Month 12</title>
        <description>The efficacy of the dietary treatment was assessed by looking at the number of participants who flared.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Time and Attention + Active Fructooligosaccharide Supplement</title>
            <description>Time and attention + active fructooligosaccharide supplement.&#xD;
Time and attention + active fructooligosaccharide supplementation: 2 teaspoons of fructooligosaccharides daily</description>
          </group>
          <group group_id="O2">
            <title>Time and Attention + Fructooligosaccharide Placebo</title>
            <description>Time and attention + fructooligosaccharide placebo&#xD;
Time and attention + fructo-oligosaccharide placebo: 2 teaspoons of placebo powder daily</description>
          </group>
          <group group_id="O3">
            <title>Dietary Therapy + Fructooligosaccharide Placebo</title>
            <description>Dietary therapy + fructooligosaccharide placebo&#xD;
dietary therapy + fructo-oligosaccharide placebo: Medical nutrition therapy and 2 teaspoons of placebo powder</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Flare Up of Crohn's Disease Through Month 12</title>
          <description>The efficacy of the dietary treatment was assessed by looking at the number of participants who flared.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quality of Life in Patients Taking Dietary Treatments</title>
        <description>Inflammatory Bowel Disease Questionnaire (IBDQ) overall scores at the exit visit of the study.It consists of 32 questons divided into four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items) and social function (5 items). Every question has graded responses from 1 (worst situation) to 7 (best situation), and thus the total score is ranging from 32 to 224 with higher scores representing better quality of life.</description>
        <time_frame>At exit visit of study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Time and Attention and Active Fructooligosaccharide Supplement</title>
            <description>Subjects received an active prebiotic fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.</description>
          </group>
          <group group_id="O2">
            <title>Time and Attention and Fructo-oligosaccharide Placebo</title>
            <description>Subjects received a placebo fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.</description>
          </group>
          <group group_id="O3">
            <title>Dietary Therapy and Fructooligosaccharide Placebo</title>
            <description>Subjects received a placebo fructo-oligosaccharide supplement and a restrictive anti-inflammatory diet developed by the research team.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life in Patients Taking Dietary Treatments</title>
          <description>Inflammatory Bowel Disease Questionnaire (IBDQ) overall scores at the exit visit of the study.It consists of 32 questons divided into four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items) and social function (5 items). Every question has graded responses from 1 (worst situation) to 7 (best situation), and thus the total score is ranging from 32 to 224 with higher scores representing better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.17" spread="24.78"/>
                    <measurement group_id="O2" value="197.42" spread="22.55"/>
                    <measurement group_id="O3" value="196" spread="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety of Dietary Treatments</title>
        <description>Data not collected</description>
        <time_frame>90 days</time_frame>
        <population>Data not Collected</population>
        <group_list>
          <group group_id="O1">
            <title>Time and Attention + Active Fructooligosaccharide Supplement</title>
            <description>Time and attention + active fructooligosaccharide supplement.&#xD;
Time and attention + active fructooligosaccharide supplementation: 2 teaspoons of fructooligosaccharides daily</description>
          </group>
          <group group_id="O2">
            <title>Time and Attention + Fructooligosaccharide Placebo</title>
            <description>Time and attention + fructooligosaccharide placebo&#xD;
Time and attention + fructo-oligosaccharide placebo: 2 teaspoons of placebo powder daily</description>
          </group>
          <group group_id="O3">
            <title>Dietary Therapy + Fructooligosaccharide Placebo</title>
            <description>Dietary therapy + fructooligosaccharide placebo&#xD;
dietary therapy + fructo-oligosaccharide placebo: Medical nutrition therapy and 2 teaspoons of placebo powder</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Dietary Treatments</title>
          <description>Data not collected</description>
          <population>Data not Collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Ileocolonic Flora</title>
        <description>Data not collected</description>
        <time_frame>90 days</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Time and Attention + Active Fructooligosaccharide Supplement</title>
            <description>Time and attention + active fructooligosaccharide supplement.&#xD;
Time and attention + active fructooligosaccharide supplementation: 2 teaspoons of fructooligosaccharides daily</description>
          </group>
          <group group_id="O2">
            <title>Time and Attention + Fructooligosaccharide Placebo</title>
            <description>Time and attention + fructooligosaccharide placebo&#xD;
Time and attention + fructo-oligosaccharide placebo: 2 teaspoons of placebo powder daily</description>
          </group>
          <group group_id="O3">
            <title>Dietary Therapy + Fructooligosaccharide Placebo</title>
            <description>Dietary therapy + fructooligosaccharide placebo&#xD;
dietary therapy + fructo-oligosaccharide placebo: Medical nutrition therapy and 2 teaspoons of placebo powder</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Ileocolonic Flora</title>
          <description>Data not collected</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Time and Attention + Active Fructooligosaccharide Supplement.</title>
          <description>Time and attention + active fructooligosaccharide supplement.&#xD;
Time and attention + active fructooligosaccharide supplementation: 2 teaspoons of fructooligosaccharides daily</description>
        </group>
        <group group_id="E2">
          <title>Time and Attention + Fructooligosaccharide Placebo</title>
          <description>Time and attention + fructooligosaccharide placebo&#xD;
Time and attention + fructo-oligosaccharide placebo: 2 teaspoons of placebo powder daily</description>
        </group>
        <group group_id="E3">
          <title>Dietary Therapy + Fructooligosaccharide Placebo</title>
          <description>Dietary therapy + fructooligosaccharide placebo&#xD;
dietary therapy + fructo-oligosaccharide placebo: Medical nutrition therapy and 2 teaspoons of placebo powder</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's flare up</sub_title>
                <description>Subject presented with abdominal pain, diarrhea, nausea and vomiting felt to be either a Crohn's flare or a viral infection. She was hospitalized for 3 days. A colonoscopy revealed active Crohn's disease confirming a flare.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Participant had a syncopal episode (felt to be vasovagal) after a bowel movement at home. Participant had a history of vasovagal syncope before the trial. She fell and hit her head during the syncope and fully recovered. Was hospitalized overnight.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <description>Subject had cough fever and headache and was given Tamiflu for possible influenza. He developed nausea, vomiting possibly due to Tamiflu or infection and a fever of 103 degrees Fahrenheit. He was hospitalized for 3 days for IV fluids and antibiotics.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio vascular and Pulmonary symptoms</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" events="14" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abnormal Heart exam</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal ear exam</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine signs and symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infection- GI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abnormal abdominal exam</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" events="20" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GERD symptoms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea/Frequent BM</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Perianal and Rectal pain/discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort+pain</sub_title>
                <counts group_id="E1" events="57" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E2" events="34" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E3" events="37" subjects_affected="11" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Decrease in Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gas/Flatus</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Change in bowel habits</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urgency - Bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tenesmus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hernia - abdominal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tooth issues</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea/Vomitting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Extraintestinal Symptoms of IBD other than arthritis /arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Weight Decline</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy symptoms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection-Lip Herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infection- HPV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infection- Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infection- Shingles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infection- Genital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint pain/ MSK problems</sub_title>
                <counts group_id="E1" events="31" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" events="29" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E3" events="21" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological symptoms</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>GenitoUrinary symptoms</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abnormal exam due to URI</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infection- URI</sub_title>
                <counts group_id="E1" events="31" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" events="20" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infection-UTI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Kidney Stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin lesions</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgeries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot study, Slow recruitment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ece A Mutlu, Principal Investigator</name_or_title>
      <organization>Rush University Medical Center</organization>
      <phone>312 942 5861</phone>
      <email>Ece_Mutlu@rush.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

